Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Juni 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Licenses Aegis Therapeutics’ Intravail® Drug Delivery Technology

SANTA MONICA, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
27. Juni 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent

SANTA MONICA, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
15. Juni 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
27. März 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of Naloxone Nasal Spray

SANTA MONICA, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
20. März 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa

SANTA MONICA, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
16. März 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
09. März 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN® Nasal Spray Patents

SANTA MONICA, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
28. Februar 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder

SANTA MONICA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
06. Februar 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer

SANTA MONICA, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...
31. Januar 2017 07:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees

SANTA MONICA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...

Vorherige Seite